News

The designation was granted based on the results from an ongoing Phase Ib/II study of olverembatinib carried out in China. The study demonstrated a clinical benefit rate of

Tabuk is a fully owned subsidiary of Astra Industrial Group. Under the agreement, Tabuk will hold the marketing authorisation and will be responsible for registering, importing, and commercialising

The designation for the investigational gene therapy was granted based on positive safety and efficacy data from the Phase I study in patients with Danon Disease. A favourable

The fundraise saw the participation of new and existing investors Kineticos Ventures and MVM Partners, respectively. Kineticos Ventures president and CEO Frank Lis is joining eXmoor board as

Abiogen Pharma’s business spans across many integrated aspects: research and development, manufacturing of pharmaceuticals under its own brand or third-party contracts, and marketing of its own and licensed

This recommendation is for ZTALMY to serve as the adjunctive treatment of epileptic seizures related with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two to 17

VMX-C001 is a modified recombinant human blood clotting factor X that enables patients taking direct oral anticoagulant blood thinners to undergo emergency surgery without the risk of bleeding.

Under the partnership, the biosimilars will be developed and supplied by Alvotech while Advanz Pharma will be responsible for registration and marketing in Europe. Alvotech and Advanz’s agreement

Co-packaged with sulbactam and durlobactam injections, XACDURO is said to be the first pathogen-targeted therapy addressing Acinetobacter, including resistant strains. It is intended for use in patients aged